Arthritis, Psoriatic
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this work, we developed a series of activatable photoacoustic (PA) probes with low molecular weights (less than 438 Da), RPS1-RPS4, which can specifically chelate with Cu<sup>2+</sup> to form radicals with turn-on PA signals in the near-infrared (NIR) region.
|
31309679 |
2019 |
Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The term <i>spinocerebellar ataxia</i> encompasses a heterogeneous group of neurodegenerative disorders due to pathogenic variants in more than 100 genes, underlying 2 major groups of ataxia: autosomal dominant cerebellar ataxias (ADCA, also known as spinocerebellar ataxias [SCAs]) due to heterozygous variants or polyglutamine triplet expansions leading to adult-onset ataxia, and autosomal recessive spinocerebellar ataxias (ARCAs, also known as SCARs) due to biallelic variants, usually resulting in more severe and earlier-onset cerebellar ataxia.
|
31617442 |
2020 |
Ataxia, Spinocerebellar
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The term <i>spinocerebellar ataxia</i> encompasses a heterogeneous group of neurodegenerative disorders due to pathogenic variants in more than 100 genes, underlying 2 major groups of ataxia: autosomal dominant cerebellar ataxias (ADCA, also known as spinocerebellar ataxias [SCAs]) due to heterozygous variants or polyglutamine triplet expansions leading to adult-onset ataxia, and autosomal recessive spinocerebellar ataxias (ARCAs, also known as SCARs) due to biallelic variants, usually resulting in more severe and earlier-onset cerebellar ataxia.
|
31617442 |
2020 |
Breast Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
These results suggest that the RPS4X/YB-1 complex is a significant potential target to counteract cisplatin resistance in breast cancer.
|
21466612 |
2011 |
Breast Carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
These results suggest that the RPS4X/YB-1 complex is a significant potential target to counteract cisplatin resistance in breast cancer.
|
21466612 |
2011 |
Breast Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Three SCAR markers (BC10-1, BC13-4 and BC31-2) had high levels of genomic DNA amplification in breast cancer.
|
28410206 |
2017 |
Cerebellar Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The term <i>spinocerebellar ataxia</i> encompasses a heterogeneous group of neurodegenerative disorders due to pathogenic variants in more than 100 genes, underlying 2 major groups of ataxia: autosomal dominant cerebellar ataxias (ADCA, also known as spinocerebellar ataxias [SCAs]) due to heterozygous variants or polyglutamine triplet expansions leading to adult-onset ataxia, and autosomal recessive spinocerebellar ataxias (ARCAs, also known as SCARs) due to biallelic variants, usually resulting in more severe and earlier-onset cerebellar ataxia.
|
31617442 |
2020 |
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, high-level expression of RPS4X was associated with nonmucinous cancer cell type and that of ECT2 with lack of lymphatic invasion while upregulation of CKS2 was correlated with early tumor stage and lack of family history of CRC.
|
21304002 |
2011 |
Glial scar
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
And it could also decrease the expression of the glial scar marker glial fibrillary acidic protein (GFAP), neurocan and phosphacan in the peri-infarct region and markedly reduce the thickness of glial scar after ischemia/reperfusion (I/R).
|
28501505 |
2017 |
Gonadal Dysgenesis, 45,X
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings are consistent with the hypothesis that RPS4 deficiency has a role in Turner syndrome, a complex human phenotype associated with monosomy X.
|
8358435 |
1993 |
Gonadal Dysgenesis, 45,X
|
0.020 |
Biomarker
|
disease |
BEFREE |
There may be another gene(s) that contributes to abnormal phenotypes of monosomy X. Molecular evolutionary analysis shows that the Y-linked and RPS4X-related homologs diverged prior to the radiation of placental mammals and evolved independently.
|
8808278 |
1996 |
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among the high binding mRNA 3'-UTR segments, we analyzed the housekeeping ribosomal protein S4, X-linked [RPS4X] mRNA 3'-UTR and the 3'-UTR of galectin-1 (GAL-1) mRNA, which is known to be one of the genes upregulated in HCV-infected liver cells and to have a wide spectrum of biological properties.
|
24503063 |
2014 |
Histoplasmosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To evaluate the relevance of the SCAR markers for the diagnosis of histoplasmosis, another molecular marker (M antigen probe) was used for comparison.
|
22189121 |
2012 |
Infection by Cryptococcus neoformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast, the 1281-1283(230) SCAR marker and the M antigen probe also amplified DNA from Aspergillus niger and Cryptococcus neoformans, respectively.
|
22189121 |
2012 |
Intrahepatic Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RPS4X was significantly upregulated in ICC tissues compared with the inflamed bile duct tissues.
|
28693133 |
2017 |
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
These results suggest that the RPS4X/YB-1 complex is a significant potential target to counteract cisplatin resistance in breast cancer.
|
21466612 |
2011 |
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Three SCAR markers (BC10-1, BC13-4 and BC31-2) had high levels of genomic DNA amplification in breast cancer.
|
28410206 |
2017 |
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
CTD_human |
These results suggest that the RPS4X/YB-1 complex is a significant potential target to counteract cisplatin resistance in breast cancer.
|
21466612 |
2011 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high-level expression of RPS4X was associated with nonmucinous cancer cell type and that of ECT2 with lack of lymphatic invasion while upregulation of CKS2 was correlated with early tumor stage and lack of family history of CRC.
|
21304002 |
2011 |
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results included known markers of MS such as the myelin basic protein (MBP) and glutathione S-transferase (GST) M1, nerve growth factors, such as nerve injury-induced protein 1 (NINJ1), X-ray and excision DNA repair factors (XRCC9 and ERCC5) and X-linked genes such as the ribosomal protein, RPS4X.
|
14625084 |
2003 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high-level expression of RPS4X was associated with nonmucinous cancer cell type and that of ECT2 with lack of lymphatic invasion while upregulation of CKS2 was correlated with early tumor stage and lack of family history of CRC.
|
21304002 |
2011 |
Neurodegenerative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The term <i>spinocerebellar ataxia</i> encompasses a heterogeneous group of neurodegenerative disorders due to pathogenic variants in more than 100 genes, underlying 2 major groups of ataxia: autosomal dominant cerebellar ataxias (ADCA, also known as spinocerebellar ataxias [SCAs]) due to heterozygous variants or polyglutamine triplet expansions leading to adult-onset ataxia, and autosomal recessive spinocerebellar ataxias (ARCAs, also known as SCARs) due to biallelic variants, usually resulting in more severe and earlier-onset cerebellar ataxia.
|
31617442 |
2020 |